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Abstract
Infusion of bone marrow-derived mononuclear cells (BMMNC) has been reported to ameliorate cardiac dysfunction after
acute myocardial infarction. In this study, we investigated whether infusion of BMMNC is also effective for non-ischemic
heart failure model mice and the underlying mechanisms. Intravenous infusion of BMMNC showed transient
cardioprotective effects on animal models with dilated cardiomyopathy (DCM) without their engraftment in heart,
suggesting that BMMNC infusion improves cardiac function via humoral factors rather than their differentiation into
cardiomyocytes. Using conditioned media from sorted BMMNC, we found that the cardioprotective effects were mediated
by growth hormone (GH) secreted from myeloid (Gr-1(+)) cells and the effects was partially mediated by signal transducer
and activator of transcription 3 in cardiomyocytes. On the other hand, the GH expression in Gr-1(+) cells was significantly
downregulated in DCM mice compared with that in healthy control, suggesting that the environmental cue in heart failure
might suppress the Gr-1(+) cells function. Activin A was upregulated in the serum of DCM models and induced
downregulation of GH levels in Gr-1(+) cells and serum. Furthermore, humoral factors upregulated in heart failure including
angiotensin II upregulated activin A in peripheral blood mononuclear cells (PBMNC) via activation of NFkB. Similarly, serum
activin A levels were also significantly higher in DCM patients with heart failure than in healthy subjects and the GH levels in
conditioned medium from PBMNC of DCM patients were lower than that in healthy subjects. Inhibition of activin A
increased serum GH levels and improved cardiac function of DCM model mice. These results suggest that activin A causes
heart failure by suppressing GH activity and that inhibition of activin A might become a novel strategy for the treatment of
heart failure.
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Introduction
Heart failure is a major cause of mortality in many countries.
Infusion of bone marrow-derived mononuclear cells (BMMNC) is
expected as a novel treatment of heart failure. Animal experiments
and clinical trials have shown that BMMNC infusion ameliorates
cardiac dysfunction after acute myocardial infarction and chronic
myocardial ischemia [1]–[4]. Although the outcomes vary among
trials, recent meta-analyses revealed that cardiac function slightly
improves following BMMNC infusion for ischemic heart diseases
[5], [6].Bone marrowcellswere reported tobeincorporatedintothe
damaged myocardium and to differentiate into various cell types
including cardiomyocytes [7]. However, whether bone marrow-
derived stem cells can differentiate into many cardiomyocytes is still
an open question [8]. There are many reports indicating that
transplantation of various types of stem cells improves the cardiac
function of ischemic hearts, mainly by paracrine factors which
induce angiogenesis and cardioprotection [9]–[11]. Since the effects
of BMMNC infusion for non-ischemic cardiomyopathy remain
unknown, we examined whether BMMNC infusion also improves
cardiac function of non-ischemic cardiomyopathy.
Results
Preparation of non-ischemic dilated cardiomyopathy
(DCM) mice
Two kinds of non-ischemic DCM mice were used. The first
model was generated by transgenic overexpression of a mutant
epidermal growth factor receptor (EGFR) with C-terminal
truncation (EGFRdn). The expression of mutant EGFRdn is
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27901activated by the cardiomyocyte-specific a-myosin heavy chain
(aMHC) promoter (Figure 1A, Figure S1). EGFRdn mice
exhibited heart failure and died at 5–30 weeks of age (Figure 1B).
Gross inspection of the EGFRdn hearts showed global chamber
dilatation with marked wall thinning (Figure 1C). The heart/body
weight ratio was approximately 1.5-fold higher at 6 weeks of age in
EGFRdn mice than in wild-type mice (Figure 1D). Echocardiog-
raphy showed a significant decrease in the fractional shortening
(FS) together with chamber dilatation (Figure 1E). In the second
model, cardiomyopathy was induced by intraperitoneal injection
of doxorubicin in wild-type mice. Doxorubicin-induced cardio-
myopathy (DOX) mice showed marked dilatations of the left
ventricular diastolic and systolic dimensions, and reduction of
cardiac function (Figure S2).
Intravenous infusion of BMMNC transiently improved the
cardiac function in DCM mice
BMMNC (2.0610
7 cells) were isolated from wild-type healthy
mice and intravenously infused via the tail veins to 8-week-old
EGFRdn mice and 11-week-old DOX mice. An equal volume of
PBS was infused into control mice. Three days after infusion,
echocardiography showed that the FS was significantly improved
in BMMNC-treated EGFRdn (Figure 2A) and DOX (Figure 2A)
mice, compared with the respective controls. However, these
effects were lost by 14 d after infusion (Figure 2A). When the
infusion was repeated every 2 weeks, cardiac function showed
improvements for .50 d (Figure 2B).
Although infusion of BMMNC is not promising for the
treatment of heart failure, we may be able to apply alternative
treatment if we understand the underlying mechanisms of bene-
ficial effects of BMNNC infusion. To elucidate the mechanisms,
we infused BMMNC derived from GFP mice. Although many
GFP-positive cells were observed in the peripheral blood and the
spleen at 3 d after infusion (Figure 2C, D), none were found in the
heart, lung, liver, kidney or skeletal muscle (Figure 2E). At day 14,
few GFP-positive cells were observed even in the peripheral blood
(Figure 2C). This was consistent with the observation that
BMMNC infusion improved cardiac function at day 3, but not
at day 14. These results suggest that BMMNC infusion improves
the systolic function of DCM mice not by transdifferentiation of
BMMNC into cardiomyocytes but probably by humoral factors
secreted from BMMNC. Size of each cardiomyocyte was larger in
BMMNC-infused EGFRdn mice than in PBS-infused EGFRdn
mice when infusions were repeated every 2 weeks for 8 weeks (i.e.,
Figure 1. Transgenic overexpression of EGFRdn in the heart causes progressive heart failure. (A) Schematic representation of the cDNA
construct used to generate EGFRdn mice. The construct contains an aMHC promoter, human EGFRdn cDNA and a human growth hormone
polyadenylation signal (Hgh-pA). (B) Kaplan-Meier survival curves for wild-type (n=62) and EGFRdn (L2–5, n=19; L9–12, n=21) mice, showing a
significant reduction in the survival rates in EGFRdn mice (log rank test, P,0.0001). (C) Gross morphology of whole hearts (upper panels) and
longitudinal sections (lower panels) of hearts from wild-type and EGFRdn mice (L9–12) at 6 weeks of age. Ao, aorta; LA, left atrium; LV, left ventricle;
RA, right atrium; RV, right ventricle. Scale bars: 2 mm. (D) Heart-to-body weight ratios (HW/BW) of wild-type (n=9) and EGFRdn (L9–12, n=7) mice at
6 weeks of age. *P,0.01. (E) Echocardiographic analysis. The upper photographs show representative M-mode images. The lower graphs show the
left ventricular diastolic and systolic dimensions and FS of 8 week-old EGFRdn mice (L9–12) (n=23) and age-matched wild-type mice (n=10). LVDd,
left ventricular diastolic dimension; LVDs, left ventricular systolic dimension. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027901.g001
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density or the number of apoptotic cells in the heart between the
BMMNC-infused group and the control group (data not shown).
BMMNC-derived conditioned medium (CM) improved
cardiomyocyte contractility
To elucidate whether factors secreted from BMMNC were
involved in their beneficial effects on cardiac function, we first
examined the effects of CM from BMMNC on the contractility of
cultured cardiomyocytes of neonatal rats. After serum starvation
for 12 h, cardiomyocytes were challenged with culture medium
conditioned by BMMNC. Cell shortening was significantly
enhanced and beating rate was markedly increased at 30 min
and at 12 h after starting culture with the CM, compared with
those in untreated cells (Figure 3A), suggesting that BMMNC
secrete factors that positively affect cardiomyocyte contractility.
Flow cytometric analysis revealed that BMMNC consisted of
several cell populations including myeloid (Gr-1(+) cells, ,40%),
erythroid (TER119(+) cells, ,20%), and lymphoid cells (B220(+)
cells, ,20%) (Figure S4). The individual cell populations,
including the lineage-negative population of cells, were sorted by
magnetic beads. The isolated cells were 0.8610
7 Gr-1(+) cells,
0.4610
7 B220(+) cells, 0.2610
7 TER(+) cells, and 0.1610
7
lineage-negative cells from 2.0610
7 BMMNC. When CM was
collected from each population and added to cardiomyocytes
starved for 12 h, only the CM from Gr-1(+) cells significantly
enhanced cell shortening and increased the beating rate
(Figure 3B), suggesting that Gr-1(+) cells mainly contribute to
BMMNC-mediated improvements in cardiomyocyte contractility.
CM from Gr-1(+) cells or BMMNC isolated from wild-type mice
also induced significant hypertrophy of cardiomyocytes (Figure
S5). We next examined the effects of CM from Gr-1(+) cells on
DOX mice. At 1 and 3 d after the infusion of CM from Gr-1(+)
cells, FS was significantly improved, as with infusion of BMMNC
(Figure 3C). Furthermore, +dp/dt, as determined by catheteriza-
tion of the left ventricle, was also improved at 1 d after the
infusion, as compared with the control group (Figure 3D).
Collectively, these results indicate that factors secreted from Gr-
1(+) cells are responsible for BMMNC-induced improvements in
cardiac function in DCM mice.
Analysis of factors secreted from Gr-1(+) cells
The CM from wild-type Gr-1(+) cells significantly enhanced cell
shortening and increased the beating rate, while CM from
EGFRdn Gr-1(+) cells had marginal effects (Figure 4A). This
suggests that the factors that improve cardiomyocyte contractility
are more abundant in cells of wild-type mice than cells of EGFRdn
mice. We next performed DNA microarray analysis to identify the
factors involved in these effects. Twenty three genes showed
enhanced expression in Gr-1(+) cells from wild-type mice
compared with EGFRdn mice (Table 1). The gene which showed
the largest difference between two types of mice was growth
Figure 2. BMMNC infusion transiently improved the cardiac function of DCM mice. (A) Echocardiographic analysis. Transient
improvements of FS were observed at 3 d in the BMMNC-treated group, but not the control (PBS) group, in EGFRdn mice (left), and at 3 and 7 d in
DOX-treated mice (right). *p,0.05 versus PBS (n=8 per group). (B) Repeated-infusion experiments. BMMNC were infused every 2 weeks. A similar
pattern of improvement in FS was observed after each infusion. *p,0.05 versus PBS (n=8 per group). (C–E) Immunohistochemical analysis. (C) Left,
the number of GFP-positive BMMNC in peripheral blood (n=3). Right, photomicrographs of peripheral blood. Nuclei were stained with Hoechst
33258 (blue). Scale bars, 75 mm. (D) Images of the spleen 3 d after infusion. Many GFP-positive cells were observed in the spleen (lower photographs).
Upper photographs, negative control. Nuclei were stained with Hoechst (blue color). Scale bars, 25 mm. (E) No GFP-positive cells were observed in any
organs. Upper photographs, negative control. Middle and lower photographs, images taken at 3 and 14 d, respectively, after infusion. The vessels
were stained with smooth muscle cell actin (red). Nuclei were stained with Hoechst 33258 (blue). The photographs of muscle are merged fluorescent
and phase-contrast images. Scale bars, 75 mm. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027901.g002
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from EGFRdn mice was confirmed by quantitative RT-PCR and
ELISA (Figure 4B, C). GH levels were also lower in CM from Gr-
1(+) cells isolated from old myocardial infarction (OMI) mice and
DOX mice (Figure S6) than in CM from wild-type mice.
Consistent with the downregulation of GH secretion from Gr-
1(+) cells of heart failure mice, the serum GH levels were also
lower in models of heart failure such as DOX, EGFRdn and OMI
mice than in wild-type mice (Figure 4E).
Critical role of GH in Gr-1(+) cell-mediated
cardioprotection
We examined the role of GH in the effects of Gr-1(+) cell-
derived CM using pegvisomant, a specific inhibitor of the GH
receptor [12]. Treatment with pegvisomant abolished the
enhanced cell shortening and the increased beating rate induced
by CM from Gr-1(+) cells (Figure 5A), while the anti-IGF-1
antibody had no effects (Figure 5B). These results suggest that Gr-
1(+) cells improved the cardiomyocyte contractility via GH, but not
via IGF-1 in vitro. CM from Gr-1(+) cells activated various signaling
molecules, including Akt, extracellular signal-regulated kinase
(Erk) 1/2, Janus kinase (Jak) 2, signal transducers and activators of
transcription (Stat) 3/5 and protein kinase A (PKA) in cardiomy-
ocytes (Figure 5C), and these effects were completely abolished by
pegvisomant (Figure 5C). The addition of GH (500 pg/ml), a
concentration equivalent to that in the CM from wild-type Gr-1(+)
cells, activated the same signaling molecules (Figure 5C), suggest-
ing that CM from Gr-1(+) cells activates Akt, Erk1/2, Jak2, Stat3/
5 and PKA through the GH receptor signaling. Furthermore, the
CM from Gr-1(+) cells, as well as GH, increased the amount of
cyclic AMP (cAMP) in cardiomyocytes, which was also inhibited
by pegvisomant (Figure 5D). The improvements in cardiac
function induced by CM from Gr-1(+) cells were also abolished
by treatment with the GH inhibitor (Figure 5E), whereas the anti-
IGF-1 antibody had no effects (Figure 5F). Furthermore, the
infusion of CM from Gr-1(+) cells increased the GH levels in
serum of DCM mice (Figure 5G). These results suggest that Gr-
1(+) cells improve the cardiac contractility in vivo also through GH.
The BMMNC-mediated improvement in cardiac function of OMI
mice was also affected by treatment with pegvisomant (Figure S7),
suggesting that GH in BMMNC might have the therapeutic effects
on heart failure caused by various etiologies.
Since Stat 3 is one of the important downstream targets of the
GH receptor in cardiomyocytes (Figure 5C), we examined the
Figure 3. BMMNC-derived CM directly affects cardiomyocyte contractility. (A) Cell shortening and the beating rate of neonatal rat
cardiomyocytes were significantly increased after exposure to CM from BMMNC compared with the control (n=26 cells per group). The left and right
graphs show the results at 30 min and at 12 h after treatment, respectively. Upper graph, cell shortening. Lower graph, beating rate. (B) CM from Gr-
1(+) cells improved the cell shortening and increased the beating rate similar to that achieved by CM from BMMNC (n=27 per group). (C, D) Effects of
CM from Gr-1 cells on cardiac function in vivo. (C) Echocardiographic analysis (n=7). The infusion of CM from Gr-1(+) cells significantly improved the
FS of DOX mice at 1 and 3 d. (D) Infusion of CM from Gr-1(+) cells significantly improved the +dp/dt of DOX mice at 1 d, in vivo (n=7). n.s., not
significant. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027901.g003
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vivo in transgenic mice overexpressing a dominant-negative mutant
of STAT3 (STAT3dn) under the control of an aMHC promoter
[13]. The Gr-1(+) cell CM-mediated improvements in cardiac
function were not observed in DOX-treated STAT3dn mice
(Figure S8), indicating that the CM improves cardiac function
through activation of STAT3 in cardiomyocytes.
Upregulation of activin A in heart failure inhibits GH
expression in Gr-1(+) cells
The expression of the GH gene has been reported to be
regulated by transcription factors including pituitary transcription
activator-1 (pit-1) [14], [15], and activin A has been reported to
downregulate GH expression by reducing the stability of pit-1
[16]. Since activin A in the peripheral blood of heart failure
patients has been reported to be upregulated compared with that
in healthy controls [17], we investigated the role of activin A in the
downregulation of GH in Gr-1(+) cells. Serum activin A levels
were significantly higher in EGFRdn mice than in wild-type mice
(Figure 6A), and were also elevated in other murine models of
heart failure, including the OMI and DOX models (Figure S9).
When Gr-1(+) cells were cultured with 400 pg/ml of activin A, a
concentration equivalent to that in the peripheral blood of DCM
mice, mRNA and protein levels of GH were significantly
downregulated (Figure 6B), suggesting that activin A might be a
key mediator of the reduced expression of GH in the Gr-1(+) cells
of DCM mice. Furthermore, the serum activin A levels were
remarkably higher in DCM patients (Table S1) than in healthy
subjects (Figure 6A), while the GH levels in CM from peripheral
blood mononuclear cells (PBMNC) of DCM patients was lower
than that in healthy subjects (Figure 4D), suggesting that the
Figure 4. Analysis of secreted factors. (A) CM from Gr-1(+) cells from wild-type mice significantly improved the cell shortening and increased the
beating rate in neonatal rat cardiomyocytes, as compared with CM from Gr-1(+) cells from EGFRdn mice. Left graph, cell shortening (n=24 cells per
group). Right graph, beating rate (n=24 cells per group). (B) Quantitative RT-PCR analysis of GH mRNA in Gr-1(+) cells isolated from wild-type mice
and EGFRdn mice (n=4). (C, D) GH concentrations in (C) CM from Gr-1(+) cells isolated from wild-type mice and EGFRdn mice (n=4) and (D) CM from
PBMNC isolated from healthy (n=11) and DCM subjects (n=10). (E) GH concentration in serum from several mouse models of heart failure (n=4).
Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027901.g004
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failure patients. A recent study showed that PBMNC are a major
source of activin A in heart failure [17]. Since many humoral
factors are known to contribute to the pathophysiology of heart
failure [18], we examined whether humoral factors upregulated in
heart failure might regulate activin A expression. Angiotensin II
(AngII) (Figure 6C) and tissue necrosis factor-alpha (TNFa) (Figure
S10A) increased the activin A levels in CM of PBMNC in a dose-
dependent manner. Consistent with the previous reports [19],
AngII and TNFa activated NFkB in the PBMNC (Figure 6D and
Figure S10B) and AngII- and TNFa-induced upregulation of
activin A in PBMNC were inhibited with a NFkB inhibitory
peptide (Figure 6E and Figure S10C).
Inhibition of activin A in heart failure increases GH levels
and improves cardiac function
To elucidate the role of activin A in EGFRdn mice, anti-activin
A antibody was injected intraperitoneally for 2 weeks, with an
alternate-day treatment regimen. Inhibition of activin A signifi-
cantly increased GH protein levels in the CM from Gr-1(+) cells
(Figure 6F). Furthermore, when neonatal rat cardiomyocytes were
cultured with CM from Gr-1(+) cells isolated from anti-activin A
antibody-treated EGFRdn mice, cell shortening was enhanced and
the beating rate was increased significantly, as compared with CM
from Gr-1(+) cells without antibody treatment (Figure 6G).
Consistent with the upregulation of GH levels in Gr-1(+) cells by
anti-activin A antibody treatment, the serum GH levels in
EGFRdn mice were also increased (Figure 6H). Furthermore,
FS and +dp/dt in EGFRdn mice treated with anti-activin A
antibody were markedly improved compared with EGFRdn mice
treated with isotype control (Figure 6H). Collectively, these results
strongly suggest that inhibition of activin A improves cardiac
function in non-ischemic DCM mice by restoring GH levels.
Discussion
Functional benefits of BMMNC infusion have been reported in
human with ischemic heart diseases [2],[20]. Although we also
observed the improvement of cardiac function of DCM model
mice by BMMNC infusion, no engraftment of infused BMMNC
was observed in the heart. At 3 d after infusion, BMMNC were
only observed in the peripheral blood and spleen, but not in the
heart, and very few GFP-positive cells were observed at 14 d even
in the peripheral blood. This is consistent with the observations
that BMMNC infusion only transiently improved cardiac function
after infusion. These findings suggest that BMMNC improve
cardiac function via humoral factors rather than via transdiffer-
entiation into cardiomyocytes.
GH plays important roles in the protection of various tissues as
well as the growth and development of many organs and whole
body [21]. Serum GH levels have been reported to be low in
patients with congestive heart failure [22]. Recent animal studies
have demonstrated that GH treatment improves cardiac functions
[23], [24]. The growth and protection of cardiomyocytes are
regulated by various kinases such as Akt, Erk and Jak/Stat, and
many studies have demonstrated that activation of Akt and Erk
induces cardiac hypertrophy [25], [26] and prevents cardiomyo-
cytes from stress-induced apoptosis [27]. Transgenic mice with
cardiac-specific overexpression of the stat3 gene were reported to
show marked ventricular hypertrophy [28], while the cardiopro-
tective effects of several cytokines including granulocyte colony-
stimulating factor were reduced in mice with cardiac-specific
expression of dominant-negative stat3 [29]. In this study, we
showed that GH produced by Gr-1(+) cells activated Akt, Erk,
Jak2, Stat3/5 and PKA, and increased the levels of cAMP in
neonatal rat cardiomyocytes (Figure 5C, D). GH has been
reported to increase cAMP and activate PKA in reproductive
organs by still-unknown mechanisms [30]. Here, we found that the
beneficial effects of CM from Gr-1(+) cells on cardiac function
were inhibited in cardiac-specific STAT3dn mice, suggesting that
GH secreted by Gr-1(+) cells directly affects cardiomyocyte
contractility. It has been reported that GH exerts some functions
through the induction of IGF-1 expression [31], [32], and IGF-1
also promotes several cardioprotective effects in part by activating
the Akt/phosphatidylinositol 3-kinase pathway [33], [34]. In the
present study, the specific GH receptor inhibitor, but not anti-
IGF-1 antibody, attenuated the improvements of cardiac contrac-
tility by the treatment of CM from Gr-1(+) cells in vitro (Figure 5A,
B) and in vivo (Figure 5E, F). These findings suggest the effects of
Gr-1(+) cells-derived CM on cardiac function of DCM mice
mainly depend on GH rather than IGF-1.
It has been reported that the expression of GH gene is regulated
by pit-1 at the transcriptional level [14], [15] and that activin A
destabilizes pit-1 by phosphorylation [16]. Consistent with a
previous report showing higher serum activin A levels in heart
failure patients than in healthy controls [17], we found that serum
levels of activin A were increased while GH levels in PBMNC CM
were decreased in DCM patients. Similarly, the activin A levels
were higher in the peripheral blood of DCM mice than in wild-
type mice and activin A inhibited the production of GH in Gr-1(+)
Table 1. DNA microarray analysis.
The fold increase Gene symbol
4.9 Gh
4.3 Pdgfd
3.9 Figf
3.4 Tslp
3.2 Socs2
3.1 Lta
3.0 Bmp1
2.9 Il33
2.8 Ccl27a
2.7 Fgf20
2.6 Angpt1
2.5 Cxcl9
2.4 Il13
2.3 Fam3b
2.3 Il31
2.3 Gm6590
2.2 Spred1
2.2 Cmtm8
2.1 Kitl
2.1 Mif
2.1 Grem2
2.1 Il17d
2.1 Gdf10
2.0 Cxcl5
Each number indicates the fold-increase of gene expression in Gr-1(+) cells
isolated from wild-type mice compared with those from EGFRdn mice.
doi:10.1371/journal.pone.0027901.t001
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upregulated in heart failure, inhibits GH expression in various
tissues/cells, including BMMNC. Treatment with anti-activin A
antibody restored GH levels in Gr-1(+) cells and serum of
EGFRdn mice and improved cardiac function, suggesting that
normalizing the GH levels by inhibiting activin A is a novel
therapeutic strategy for heart failure. Since many humoral factors
such as AngII and TNFa are upregulated in heart failure and
increased activin A expression by activating NFkB, the molecules
that modulate NFkB activation might be also therapeutic targets
to restore GH levels. On the other hand, anti-activin A treatment
also increased expression levels of GH mRNA in the pituitary
(N.F. K.M., unpublished data), suggesting that upregulation of
activin A in heart failure might inhibit the expression of GH not
only in Gr-1(+) cells but also in the pituitary, and that anti-activin
A treatment might improve cardiac function of DCM mice in part
by restoring GH expression in the pituitary.
The effects of GH on heart failure have been examined in many
animal experiments and clinical trials [35]. A recent meta-analysis
revealed that GH treatment improved several clinical parameters
including left ventricular end-diastolic dimension, ejection fraction
and New York Heart Association functional class [36]. Converse-
ly, non-response to GH treatment for heart failure has been
ascribed to GH resistance [37]. In patients with cardiac cachexia,
GH levels were reported to be enhanced when compared with
non-cachectic patients and normal subjects [38]. In this study, GH
levels in heart failure mice and patients were significantly lower
than those in healthy control subjects. Moreover, GH derived
from Gr-1(+) cells improved cardiac function of heart failure
animals, suggesting that our models were in a non-cachectic state
and non-cachectic patients of heart failure might be suitable for
GH treatment. Because of only temporary improvements in
cardiac function (Figure 2A), bone marrow cell infusion might not
be an appropriate treatment for heart failure, however inhibition
Figure 5. GH mediates the cardioprotective effects of Gr-1(+) cell-derived CM. (A) Pegvisomant (PEG) treatment inhibited the Gr-1(+) cell
CM-mediated improvements cardiomyocyte cell shortening and beating rate at 30 min and at 12 h after treatment (n=27 cells per group). Left
graphs, cell shortening; right graphs, beating rate. (B) Anti-IGF-1 antibody failed to affect the Gr-1(+) cell CM-mediated improvements in cell
shortening or beating rate at 30 min or at 12 h after treatment (n=23 cells per group). Left graphs, cell shortening; right graphs, beating rate. (C) GH
and CM from Gr-1(+) cells phosphorylated Akt, Erk, Jak2, Stat3/5 and PKA in cardiomyocytes (n=3), which was inhibited by pegvisomant (n=3). (D)
GH (500 pg/ml) and CM from Gr-1(+) cells increased the cAMP concentration in cardiomyocytes (n=5), which was inhibited by pegvisomant (n=5).
(E, F) Cardiac function analysis by echocardiography (upper graphs, n=8) and catheterization (lower graphs, n=8). Pegvisomant (E), but not anti-IGF-
1 antibody (F), inhibited the improvements in FS and +dp/dt elicited by the infusion of CM from Gr-1(+) cells. *p,0.05 (n=8). (G) Serum GH
concentrations in DOX mice treated with CM from Gr-1(+) cells (n=4 per group). The infusion of CM from Gr-1(+) cells from wild-type mice increased
the serum GH concentration at 1 d, but not at 5 d. Data are means 6 s.e.m.
doi:10.1371/journal.pone.0027901.g005
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therapeutic strategies for heart failure.
We used EGFRdn for DCM model mice in this study. It has
been reported that cardiac-specific mutant of ErbB2, a member of
the EGFR/erbB family, shows a severe dilated cardiomyopathy in
mice [39]. In the clinical setting, trastuzumab, an anti-cancer
agent, is humanized monoclonal antibody that targets the
extracellular domain of the human epidermal growth factor re-
ceptor 2 and the use of trastuzumab demonstrated an unexpect-
edly high incidence of both asymptomatic and symptomatic
cardiomyopathy. EGFRdn is a compatible DCM model mouse,
resembling the cardiotoxic effects observed in patients treated with
trastuzumab [40], [41].
There is a limitation in this study. We examined the surface area
of neonatal rat cardiomyocytes after the treatment with CM from
Gr-1(+) cells or BMMNC as an index for cardiac hypertrophy.
However, the surface area not only depends on cell volume, but
also on the degree of adhesion and spreading on the culture dishes.
Materials and Methods
Ethics Statement. The ethical committee of Tokyo Women’s
Medical University reviewed and approved the study protocol
(approval ID: 1795). The study was conducted in accordance with
the Declaration of Helsinki. We obtained informed consent from
the all patients and the all healthy subjects by written before
inclusion in this study.
Animals. Wild-type mice (C57BL/6) were purchased from
Japan SLC. Adult GFP transgenic mice (C57BL/6) were a kind
gift from Dr. M. Okabe (Osaka University). Cardiac-specific
dominant-negative STAT3 mice were a kind gift from Dr. K.
Yamauchi-Takihara (Osaka University). Neonatal Wistar rats (0–
1 d old) were purchased from Saitama Experimental Animals
Supply. All protocols were approved by the Institutional Animal
Care and Use Committee of Tokyo Women’s Medical University
and Chiba University. The approval IDs for the animal
experiments were 11–34 in Tokyo Women’s Medical University
Figure 6. Regulatory mechanisms of GH in heart failure. (A) The serum activin A concentration was higher in EGFRdn mice (left, n=5) and in
DCM patients (right, n=10) than in wild-type mice (n=5) and healthy subjects (n=11). (B) Activin A downregulated GH mRNA expression in Gr-1(+)
cells and GH protein levels in Gr-1(+) cell CM. Left graph, GH protein concentration; middle photographs, representative semi-quantitative RT-PCR
images; right graph, GH mRNA expression (n=3). (C, D) AngII upregulated activin A secretion (C, n=4) and phosphorylated NFkB expression (D, n=5)
in wild-type PBMNC. (D) Left graph, total NFkB; right graph, phosphorylated NFkB. (E) Inhibition of NFkB [50 mM; NFkB p65 (Ser276) inhibitory
peptide] suppressed AngII (10 mM)-mediated upregulation of activin A in CM derived from wild-type PBMNC (n=5). Isotype peptide was used as
control. (F) The GH concentration in CM from EGFRdn Gr-1(+) cells (n=5) was significantly increased by treatment with an anti-activin A antibody
(n=5). (G) Effects of anti-activin A antibody treatment on cell shortening and the beating rate of cardiomyocytes induced by CM from Gr-1(+) cells
isolated from EGFRdn mice (n=18 cells per group). (H) Treatment with the anti-activin A antibody improved the cardiac function of EGFRdn mice. Left
graph, echocardiography (n=7). Middle graph, miller catheter results (n=7). Right graph, serum GH concentration in EGFRdn mice after antibody
treatment (n=7). Data are means 6 s.e.m. (I) Proposed mechanism underlying impaired GH expression by activin A in heart failure.
doi:10.1371/journal.pone.0027901.g006
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weight) was intraperitoneally injected into wild-type male mice
(C57BL/6) once-weekly at weeks 7 and 8 after birth. After both
Doxorubicin injections, the mice were reared for a further 2 weeks,
and the surviving mice were used for experiments. Myocardial
infarction models were prepared using wild-type male mice
(C57BL/6) as previously described [11]. Serum and Gr-1(+) cells
were isolated 4 weeks after inducing myocardial infarction (11
weeks of age).
Generation of EGFRdn mice. The C-terminal 533 amino
acids [42] were deleted from the full-length human EGFR cDNA
(a gift from Professor T. Kadowaki, The University of Tokyo) by
introducing a stop codon (TGA) after the R677 codon by site-
directed mutagenesis. The truncated EGFR (EGFRdn) cDNA was
then subcloned into the aMHC promoter-containing expression
vector (a gift from Professor J. Robbins, Cincinnati Children’s
Hospital). The 8.2-kb DNA fragment was microinjected as a
transgene into pronuclei of eggs from BDF1 mice. The eggs were
then transferred into the oviducts of pseudopregnant ICR mice.
The transgenic founders were identified by Southern blot and
PCR analysis. Line 2–5 and Line 9–12 were established and
maintained by breeding to C57BL/6 mice. Line 9–12 was selected
for further analysis on the basis of a higher level of transgene
expression.
BMMNC infusion and CM injection. BMMNC (2.0610
7)
isolated from a male wild-type mouse and suspended in 200 mlo f
PBS or an equal volume of PBS as a control were injected into the
tail veins of anesthetized (4% inhaled isoflurane) 8-week-old male
EGFRdn mice and 11-week-old male DOX and OMI mice. CM
(200 ml) from Gr-1(+) cells from male wild-type mice or isovolume
serum-depleted DMEM were infused into the tail veins of
anesthetized 8-week-old male EGFRdn mice and 11-week-old
male DOX mice under anesthesia. Anti-mouse insulin-like growth
factor-1 (IGF-1) (0.1 mg/g body weight) or anti-goat immuno-
globulin G (IgG) (0.1 mg/g body weight) antibodies were
intraperitoneally injected into 11-week-old male DOX mice 2 h
before CM infusion. Anti-activin A (20 mg) or anti-mouse IgG
(20 mg) antibodies were intraperitoneally injected at 48-h intervals
into male EGFRdn mice from 10 to 12 weeks of age. Pegvisomant
(10 mg/kg body weight) or vehicle (control) were intraperitoneally
injected into 8-week-old male DOX mice 30 min before CM
infusion.
Evaluation of cell shortening and the beating rate of
cardiomyocytes. After 12 h starvation with 500 ml serum-
depleted DMEM in 12-well dishes, rat cardiomyocytes were
cultured with 500 ml of CM or serum-depleted DMEM. At specific
times, the cultured cardiomyocytes were video recorded for 10 sec,
and the percentage of cell shortening was analyzed using
ImageExpress version 5.5 (Nippon Roper). To measure the
percentage of cell shortening, two regions of interest were fixed
by the software, which analyzed the beating distance of a single
cardiomyocyte, and divided the distance by the length between the
regions of interest. The number of beats of single cardiomyocyte
was counted for 10 sec to determine the beating rate. For antibody
treatment in vitro, the starved cardiomyocytes were pretreated with
anti-IGF-1 (10 mg/ml) or anti-goat IgG (10 mg/ml) antibodies for
2 h before adding CM. For pegvisomant treatment in vitro, the
cardiomyocytes were pretreated with pegvisomant (12.5 mg/ml)
for 30 min before adding CM.
Echocardiography and catheterization. Transthoracic
echocardiographic analysis and catheterization analysis were
performed as previously described [11]_ENREF_9. Briefly, the
+dp/dt in the left ventricle was measured using a catheter, which
was introduced retrogradely via the carotid artery.
Cell isolation. Neonatal rat cardiomyocytes were isolated and
separately collected as described previously [43]. Cardiomyocytes
were plated at a density of 1610
5 cells/cm
2 on six-, 12- and 24-
well dishes (BD Falcon) coated with 1% gelatin and cultured in
DMEM supplemented with 10% FBS. Adult cardiomyocytes were
prepared as previously described [44]. BMMNC and PBMNC
were isolated from 8-week-old male C57BL/6, male GFP mice,
and male EGFRdn mice by density gradient centrifugation with
Histopaque-1083, as previously described [45]. PBMNC were also
isolated from human subjects, as previously described [46].
Sorting of harvested BMMNC into sub-populations
and collection of CM. After BMMNC were harvested from
male wild-type mice, the cells were sorted into Gr-1(+) cells,
B220(+) cells, TER(+) cells, and lineage-negative populations using
a Magnetic Cell Sorting system (Miltenyi Biotec), as previously
described [47]. To collect the CM, the individual sub-populations
were seeded onto 24-well dishes with 200 ml of serum-depleted
DMEM. After incubation for 24 h in serum-depleted DMEM, the
supernatant (CM) was collected, and any cells were removed by
filtering through a 0.45-mm filter (BD Falcon).
Phase-contrast live imaging. Live images of beating
cardiomyocytes were taken using a Leica inverted microscope
(Leica) equipped with a phase-contrast objective and a CCD
camera (Leica).
Flow cytometry. The percentage of cells expressing each cell
surface antigen was analyzed using a FACSCalibur (Becton
Dickinson Immunocytometry Systems) and Cell Quest Pro version
5.2 software.
RNA extraction and DNA microarray analysis. Total
RNA was extracted from 12-week-old male wild-type (n=4) and
age-matched male EGFRdn mice (n=4) using a RNeasy Mini Kit
(Qiagen) according to the manufacturer’s protocol. RNA quality
was assessed with an Agilent 2100 Bioanalyzer (Agilent Technol-
ogies). cRNA preparation, fragmentation, hybridization, and
scanning of a GeneChipH Mouse Genome 430 2.0 Arrays
(Affymetrix) were performed according to the manufacturer’s
protocol. cRNA was labeled using a Two-cycle Eukaryotic Target
Labeling assay with a GeneChip Expression 39 amplification two-
cycle labeling and control reagents kit (Affymetrix). Briefly, cDNA
was generated from total RNA (100 ng) using SuperScript II
(Invitrogen) and a T7-oligo(dT) promoter primer (Affymetrix).
After second-strand cDNA synthesis, cDNA was converted to
cRNA by an in vitro transcription reaction (MEGAscript T7 kit,
Ambion). The cRNA was then purified using a Sample Cleanup
Module (Affymetrix), and the yield was monitored with a
spectrophotometer. The second cycle of cDNA synthesis was
performed, followed by the same cleanup as above and a second in
vitro transcription reaction cycle with biotin-labeled ribonucleotides
and T7 RNA polymerase. The labeled cRNA was purified, using a
Sample Cleanup Module and denatured at 94uC before
hybridization. The samples were hybridized to GeneChipH Mouse
Genome 430 2.0 Arrays at 45uC for 16 h with rotation at 60 rpm.
The arrays were then washed, stained with phycoerythrin–
streptavidin (Molecular Probes), washed, and scanned with a
GeneChip Scanner 3000 7G (Affymetrix). The data were analyzed
with GeneSpring version 7.3.1 software (Agilent Technologies).
Reverse transcriptase-PCR. RNA extraction and RT-PCR
were performed as previously described [11]. Real-time PCR
amplification was performed using an Applied Biosystems 7500
real-time PCR system (Applied Biosystems) with QuantiTect
SYBR Green PCR Master Mix (Qiagen). The PCR protocol
comprised an initial denaturation step (94uC, 15 sec) followed by
60 cycles of amplification and quantification (55uC for 30 sec and
72uC for 35 sec) and a melting curve program (60–95uC). The
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curve of GAPDH. All samples were independently analyzed at
least three times for each gene. Semi-quantitative RT-PCR of GH
was performed using 0.4 mg of total RNA and followed by 40
cycles of the above conditions. The primer sequences were
QT00311654 (Qiagen) for GH in real-time PCR, 59-TCCTG-
TGGACAGATCACTGC-39 and 59-AATGTAGGCACGCTC-
GAACT-39 for GH in semi-quantitative PCR, QT00309099
(Qiagen) for GAPDH, and 59-GGACCTGGCTGGCCGGGA-
CC-39 and 59-GCGGTGCACGATGGAGGGGC-39 for b-actin.
For semi-quantitative RT-PCR, the PCR products were size-
fractionated by 2% agarose gel electrophoresis.
Northern blot analysis. For northern blot analysis, total
RNA (20 mg) was extracted from hearts using TRIzol Reagent
(Invitrogen) and hybridized with a cDNA probe for EGFRdn. 18S
rRNA ethidium bromide staining was used to quantify RNA
loading.
Analysis of phosphorylated ErbB receptor expression.
Four-week-old mice were anesthetized by intraperitoneal injection
of urethane (2 mg/g body weight) followed by intravenous
injection of HB-EGF (0.5 mg/g body weight, R&D Systems),
NRG-1b (0.5 mg/g body weight, R&D Systems), or vehicle via the
inferior vena cava. After 5 min, the hearts were immediately
excised and homogenized in a buffer containing 50 mmol/l
HEPES (pH 7.5), 137 mmol/l NaCl, 1 mmol/l MgCl2, 1 mmol/l
CaCl2, 10 mmol/l Na-pyrophosphate, 2 mmol/l EDTA, 1% NP-
40, 10% glycerol, 2 mmol/l Na3VO4, 10 mmol/l NaF, and
protease inhibitor cocktail (Complete Mini, Roche Applied
Science). To analyze the tyrosine phosphorylation of ErbB
receptors, equivalent amounts of proteins were subjected to
immunoprecipitation with the specific antibodies, fractionated by
6% SDS-PAGE, and immunoblotted with the mouse monoclonal
anti-phosphotyrosine antibody 4G10 (Millipore). Horseradish
peroxidase-conjugated anti-mouse IgG antibody (GE Healthcare)
was used as the secondary antibody, and the bound antibodies
were detected using an ECL detection kit (GE Healthcare).
ELISA. Serum and CM concentrations of cAMP, GH and
activin A were measured by ELISA (cAMP and activin A, R&D
Systems; GH, LINCO Research). To prepare cell lysates for
cAMP analysis, cardiomyocytes were seeded (4610
5 cells/cm)
onto six-well dishes coated with 1% gelatin and cultured in
DMEM supplemented with 10% FBS. After 5 d, the cells were
washed three times with PBS and the medium was changed to
serum-depleted DMEM. After incubation for 12 h in the serum-
depleted medium, the cells were washed three times with PBS and
the medium was replaced with 1 ml of serum-depleted DMEM
with CM (1 ml), 2 ml of serum-depleted DMEM with 500 pg/ml
GH, 2 ml of serum-depleted DMEM with 12.5 mg/ml pegviso-
mant, or 1 ml of serum-depleted DMEM plus 1 ml of CM and
12.5 mg/ml pegvisomant. Thirty minutes later, the cardiomyo-
cytes were resuspended in lysis buffer in six-well dish.
To examine the expression of NFkB and phosphorylated NFkB
in PBMNC, PBMNC isolated from wild-type male mice were
cultured with AngII or TNFa. Thirty minutes later, PBMNC were
resuspended in lysis buffer and the expression of NFkB and
phosphorylated NFkB were examined using sandwich ELISA kits
(Cell Signaling). Some cells were also treated with 50 mMN F kB
p65 (Ser276) inhibitory peptide to inhibit NFkB activity.
Western blot analysis. Whole-cell lysates (30–50 mg) were
resolved by SDS-PAGE. The separated proteins were transferred
to a PVDF membrane (GE Healthcare) and incubated with the
primary antibody, followed by an anti-IgG-horseradish peroxi-
dase-conjugated secondary antibody. Proteins were detected using
an ECL-Plus kit (GE Healthcare).
Immunohistology. The hearts were fixed with 4% parafor-
maldehyde and embedded in paraffin, or fixed in 10% neutralized
formalin and embedded in Tissue-Tek OCT cryo-embedding
compound (Sakura Finetek). The specimens were sectioned (5 mm
thick), and stained with hematoxylin/eosin or Masson trichrome.
Evaluation of cardiac hypertrophy. To evaluate the mean
diameter of LV cardiomyocytes, the shortest diameter of each
cardiomyocyte was measured in nucleated transverse sections
stained with hematoxylin-eosin. Thirty cardiomyocytes in each LV
were measured using an ocular micrometer disc with a linear scale
at a magnification of 4006, and the average cardiomyocyte
diameter was calculated for each specimen. Four hearts were
measured in each group. The cell surface area of isolated neonatal
and adult cardiomyocytes was measured by planimetry in 50
randomly selected cells per specimen.
Immunofluorescence staining. Immunostaining was per-
formed as previously described [45]. Images were taken using a
fluorescent microscopy (Leica) with LAS AF software (Leica).
Human subjects. We enrolled 10 subjects who were
outpatients of Department of Cardiology of Tokyo Women’s
Medical University Hospital. We obtained 10 ml of whole blood
from each patient. Half of the blood sample was used to measure
the serum activin A concentration and the remaining blood was
used to measure GH in CM after PBMNC isolation. All patients
were receiving medical therapies and exhibited New York Heart
Association class II symptoms. We also enrolled 11 healthy age-
and body mass index-matched volunteers. Characteristics of the
patients and healthy subjects are summarized in Table S1.
Statistics. Data are presented as means 6 s.e.m. We
examined differences between groups by Student’s t test or
analysis of variance followed by Bonferroni’s correction to
compare means. A value of P,0.05 was considered to be
significant.
Supporting Information
Figure S1 Overexpression of EGFRdn inhibited the
functional activation of endogenous ErbB receptors in
a dominant-negative manner. (A) Northern blot analysis for
the transgene expression in hearts from wild-type and two different
founder lines of EGFRdn mice (L2–5 and L9–12). (B) Tyrosine
phosphorylation of ErbB receptors in hearts from wild-type and
EGFRdn mice (L9–12) at 5 min after injection of HB-EGF. In
wild-type mice, intravenous injection of HB-EGF enhanced
cardiac tyrosine phosphorylation of EGFR, ErbB2 and ErbB4,
which was abrogated in EGFRdn hearts. HB-EGF, heparin-
binding EGF-like growth factor. (C) Tyrosine phosphorylation of
ErbB receptors in hearts from wild-type and EGFRdn mice (L9–
12) at 5 min after the injection of NRG-1b. NRG-1b induced
tyrosine phosphorylation of ErbB2 and ErbB4 in wild-type hearts,
but not in EGFRdn hearts. NRG-1, neuregulin-1.
(TIF)
Figure S2 Echocardiographic analysis of DOX mice. (A)
Representative M-mode images of wild-type and DOX mice. (B)
Left ventricular diastolic and systolic dimensions, and FS of 11-
week-old DOX mice (n=36) and age-matched wild-type mice
(n=10). LVDd, left ventricular diastolic dimension; LVDs, left
ventricular systolic dimension. Data are means 6 s.e.m.
(TIF)
Figure S3 Analysis of cardiac hypertrophy. (A) The
shortest diameter of each cardiomyocyte (n=30 per group). Lower
photographs, H&E-stained tissue sections. Scale bar, 75 mm. (B)
Surface area of isolated adult cardiomyocytes (n=50 per group).
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Data are means 6 s.e.m.
(TIF)
Figure S4 Flow cytometric analysis. The left and right
panels show the expression of each cell surface marker before and
after magnetic sorting (MACS), respectively.
(TIF)
Figure S5 Cardiac hypertrophy in vitro. Upper graph, cell
surface area of neonatal rat cardiomyocytes (n=50); lower
photographs, representative images of the cells. Cardiomyocytes
were stained with sarcomeric a-actinin (red). Nuclei were stained
with Hoechst 33258 (blue). Scale bars, 75 mm. Data are means 6
s.e.m.
(TIF)
Figure S6 Comparison of GH concentration. GH concen-
tration in CM from Gr-1(+) cells isolated from old myocardial
infarction (OMI) mice and DOX mice (n=5). Data are means 6
s.e.m.
(TIF)
Figure S7 BMMNC improve the cardiac function of
OMI mice via the GH receptor. (A) At 4 weeks after coronary
ligation, BMMNC were infused via the tail vein. Pegvisomant
(10 mg/kg body weight) or vehicle (control) was intraperitoneally
injected into OMI mice 30 min before infusing BMMNC.
BMMNC infusion improved FS and +dp/dt at 3 d after infusion
and these improvements were inhibited by pegvisomant (n=5). (B)
Masson trichrome staining. Panels show representative images.
Scale bars: 1 mm. Data are means 6 s.e.m.
(TIF)
Figure S8 Direct effects of GH in the CM from Gr-1(+)
cells on cardiomyocytes. CM from Gr-1(+) cells from wild-type
mice was infused into DOX-treated wild-type mice (wild-DOX) or
DOX-treated cardiac-specific STAT3dn mice (STAT3dn-DOX).
Gr-1(+) cell-derived CM improved FS (left) and +dp/dt (right) in
wild-DOX mice (n=5) at 1 d after infusion, but not in STAT3dn-
DOX (n=5). Data are means 6 s.e.m.
(TIF)
Figure S9 Serum activin A concentrations (n=5). Data are
means 6 s.e.m.
(TIF)
Figure S10 TNFa increases the secretion of activin A
from PBMNC via NFkB. (A) Activin A levels in CM from
PBMNC were upregulated by treatment with TNFa (n=5). (B)
TNFa (50 ng/ml) activated NFkB in PBMNC (n=5). Left, total
NFkB; right, phosphorylated NFkB. (C) TNFa (50 ng/ml)
-mediated upregulation of activin A in PBMNC was inhibited
by treatment with the NFkB inhibitory peptide (n=5). Isotype
peptide was used as control. Data are means 6 s.e.m.
(TIF)
Table S1 Characteristics of human subjects.
(PDF)
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